Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody

Human Gene Therapy

Volumn 24, Issue 8, 2013, Pages 751-760

  Li, Wei ^a,b   Fan, Dongmei ^a   Yang, Ming ^a   Yan, Yan ^a   Shi, Ruizan ^c   Cheng, Junping ^b   Li, Zhenzhen ^a   Zhang, Mengnan ^a   Wang, Jianxiang ^a   Xiong, Dongsheng ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 CD19 ANTIBODY; CD69 ANTIGEN; CD86 ANTIGEN; CYTARABINE; FAS ANTIGEN; FAS LIGAND; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PERFORIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT LEUKOCYTE CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LEUKEMIA; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; LOW DRUG DOSE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL DESTRUCTION; UPREGULATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE, TUMOR; CYTARABINE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LEUKEMIA; LYMPHOCYTE ACTIVATION; MICE; MICE, NUDE; MICE, SCID; T-LYMPHOCYTES;

EID: 84882395124     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.051     Document Type: Article

References (38)

1. Allison, J.P. (1994). CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol. 6, 414-419.
2. Badn, W., Kallioma? ki, S., Widegren, B., and Sjo? gren, H.O. (2006). Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin. Cancer Res. 12, 4714-4719.
3. Bargou, R., Leo, E., Zugmaier, G., et al. (2008). Tumor regression in cancer patients by very low doses of a T-cell-engaging antibody. Science 321, 974-977.
4. Baumann, K., Pfisterer, J., Wimberger, P., et al. (2011). Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol. Oncol. 123, 27-32.
5. Chambers, C.A., Krummel, M.E., Boitel, B., et al. (1996). The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol. Rev. 153, 27-46.
6. Chen, S., Rao, Q., Wang, J.X., and Wang, M. (2005). [Construction and expression of single chain variable fragments (ScFv) against human CD19 antigen] [Article in Chinese]. Sheng Wu Gong Cheng Xue Bao (Chin. J. Biotechnol.) 21, 686-691.
7. Ding, Z.C., Blazar, B., Mellor, A., et al. (2010). Chemotherapy rescues tumor-driven aberrant CD4+ T cell differentiation and restores an activated polyfunctional helper phenotype. Blood 115, 2397-2406.
8. Emens, L.A. (2010). Chemoimmunotherapy. Cancer J. 16, 295-303.
9. Fong, T.C., Wu, Y., and Kipps, T.J. (1996). Identification of a promoter element that regulates tissue-specific expression of the human CD80 (B7.1) gene. J. Immunol. 157, 4442-4450.
10. Ghiringhelli, F.M., Larmonier, N., Schmitt, E., et al. (2004). CD4+ CD25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344.
11. Ghiringhelli, F.M., Menard, C., Puig, P.E., et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25 + regulatory T cells and restores T and NK effector function in end-stage cancer patients. Cancer Immunol. Immunother. 56, 641-648.
12. Girgis, M.D., Kenanova, V., Olafsen, T., et al. (2011). Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. Surg. Res. 170, 169-178
13. Herold, M., McPherson, K., and Reichardt, H. (2006). Glucocorticoids in T-cell apoptosis and function. Cell Mol. Life Sci. 63, 60-72.
14. Holliger, P., Prospero, T., and Winter, G. (2003). ''Diabodies'': small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444-6448.
15. Li, J., Liu, Z., Jiang, S., et al. (1999). T suppressor lymphocytes inhibit NF-kappa B-mediated transcription of CD86 gene in APC. J. Immunol. 163, 6386-6392.
16. Li, W., Fan, D., Yang, M., et al. (2012). Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity. Cell. Oncol. (Dordr.) 35, 423-434.
17. Liu, J., Yang, M., Wang, J., et al. (2009). Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli. Cancer Immunol. Immunother. 58, 1761-1769.
18. Molldrem, J.J., Lee, P.P., Wang, C., et al. (2000). Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6, 1018-1023.
19. Nagorsen, D., and Baeuerle, P.A. (2011). Immunomodulatory therapy of cancer with T-cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 317, 1255-1260 [Review].
20. Niu, H., Cattoretti, G., and Dalla-Favera, R. (2003). BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells. J. Exp. Med. 198, 211-221.
21. Osada, T., Hsu, D., Hammond, S., et al. (2010). Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br. J. Cancer 102, 124-133.
22. Otero, D.C., and Rickert, R.C. (2003). CD19 function in early and late B cell development. II. CD19 facilitates the pro-B/pre-B transition. J. Immunol. 171, 5921-5930.
23. Otero, D.C., Anzelon, A.N., and Rickert, R.C. (2003). CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19- dependent survival signals. J. Immunol. 170, 73-83.
24. Pentcheva-Hoang, T., Egen, J.G., Wojnoonski, K., and Allison, J.P. (2004). B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 21, 401-413.
25. Pfreundschuh,M., Kuhnt, E., Tru?mper, L., et al. (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12, 1013-1022.
26. Qu, Y.H., Li, Y., Wu, Y.F., et al. (2010). [Influence of FccRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells] [Article in Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chin. J. Exp. Hematol.) 18, 1269-1274.
27. Rezvani, K., Grube, M., Brenchley, J.M., et al. (2003). Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102, 2892-2900.
28. Richards, J.O., Karki, S., Lazar, G.A., et al. (2008). Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517-2527.
29. Seo, N., and Tokura, Y. (1999). Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles. J. Interferon. Cytokine Res. 19, 555-561.
30. Sharabi, A., Laronne-Bar-On, A., Meshorer, A., and Haran- Ghera, N. (2010). Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev. Res. (Phila) 3, 1265-1276.
31. Tretter, C.P., Lewis, L.D., Fisher, J., et al. (2003). Taxanes synergize with the bispecific antibody MDXH447 to enhance antibody-dependent cell-mediated cytotoxicity. J. Chemother. 15, 472-479.
32. van der Most, R.G., Curie, A., Cleaver, A., et al. (2009). Cyclophosphamide chemotherapy sensitizes tumor cells to TRAILdependent CD8 + T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 4, e6982.
33. Vereecque, R., Saudemont, A., and Quesnel, B. (2004). Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 18, 1223-1230.
34. Xu, Y., Xiong, D., Yang, C., et al. (2001). [The mutation of anti- CD3 antibody (HIT3a) gene and its expression] [Article in Chinese]. Zhonghua Xue Ye Xue Za Zhi (Chin. J. Hematol.). 22, 252-255.
35. Yang, M., Fan, D.M., Gao, Y.D., et al. (2009). [The influence of Ara-C on anti-CD3/anti-Pgp mediating T-lymphocytes activities against multi-drug resistant leukemia cells] [Article in Chinese]. Zhonghua Xue Ye Xue Za Zhi (Chin. J. Hematol.) 30, 812-815.
36. Yarovinsky, T.O., Monick, M.M., and HunninIghake, G.W. (2003). Integrin receptors are crucial for the restimulation of activated T lymphocytes. Am. J. Respir. Cell Mol. Biol. 28, 607-615.
37. Zhu, J., and Paul, W.E. (2008). CD4 T cells: fates, functions, and faults. Blood 112, 1557-1569.
38. Zou, W. (2006). Regulatory T cells, tumor immunity, and immunotherapy. Nat. Rev. Immunol. 6, 295-307.